×
About 655 results

ALLMedicine™ Acquired Hemophilia Center

Research & Reviews  214 results

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in pat...
https://doi.org/10.1016/j.jtha.2022.10.004
Journal of Thrombosis and Haemostasis : JTH; Shima M, Amano K et. al.

Jan 26th, 2023 - Emicizumab is a bispecific antibody that mimics the cofactor function of activated factor (F) VIII. It prevents bleeds in patients with congenital hemophilia A regardless of the inhibitor status; however, no prospective clinical studies have been ...

The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inh...
https://doi.org/10.3324/haematol.2022.281895
Haematologica Bou-Jaoudeh M, Delignat S et. al.

Jan 20th, 2023 - Neutralizing anti-factor VIII (FVIII) antibodies, known as FVIII inhibitors, represent a major drawback of replacement therapy in persons with congenital hemophilia A (PwHA), rendering further infusions of FVIII ineffective. FVIII inhibitors can a...

Acquired Hemophilia A: A Retrospective Multicenter Analysis of 42 Patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893059
Clinical and Applied Thrombosis/hemostasis : Official Jou... Liu Y, Ruan X et. al.

Jan 20th, 2023 - Immunosuppressive therapy (IST) for acquired hemophilia A (AHA) results in remission within days to months in 60% to 80% of patients. However, little is known regarding the predictors of response. This study aimed to identify the factors that infl...

Approach to Bleeding in the Hospitalized Patient.
https://doi.org/10.1182/blood.2021014766
Blood Samuelson Bannow BT, Konkle BA

Jan 19th, 2023 - Excessive bleeding is relatively common in adult inpatients, whether as the primary reason for admission or developing during the hospital stay. Common causes include structural issues, medication effects and systemic illnesses but occasionally un...

Emicizumab in Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT04188639

Jan 9th, 2023 - This study is an international, multicenter, open-label, single arm, prospective clinical trial and will evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (A...

see more →

Guidelines  1 results

International recommendations on the diagnosis and treatment of patients with acquired ...
https://doi.org/10.3324/haematol.2008.001743
Haematologica Huth-Kühne A, Baudo F et. al.

Apr 2nd, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  11 results

Emicizumab in Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT04188639

Jan 9th, 2023 - This study is an international, multicenter, open-label, single arm, prospective clinical trial and will evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (A...

Study of TAK-672 in Participants With Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT04580407

Dec 29th, 2022 - The main aims of the study are to learn if TAK-672 can control bleeds in participants with acquired hemophilia A and if the participants have side effects from TAK-672. Acquired hemophilia A is when people's immune system attacks specific proteins...

Emicizumab in Patients With Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT05345197

Sep 10th, 2022 - Patients with AHA who are eligible will receive two loading doses of the study drug, emicizumab (6mg/kg on day 1 and 3 mg/kg on day 2) followed by once weekly subcutaneous emicizumab (1.5 mg/kg). Immunosuppression will be given concurrently as per...

Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
https://clinicaltrials.gov/ct2/show/NCT04805021

Jan 11th, 2022 - Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused by the sometimes ...

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT02610127

Aug 5th, 2021 - This study is a multi-center, uncontrolled, open-label, non-interventional post-marketing safety surveillance study to describe the use of Obizur in patients with acquired hemophilia A (AHA), and secondarily, where data are available, to describe ...

see more →

News  25 results

Rituximab for Acquired Hemophilia A in the Setting of Bullous Pemphigoid
https://www.mdedge.com/dermatology/article/256573/mixed-topics/rituximab-acquired-hemophilia-setting-bullous-pemphigoid
Maria C. Bell, MD, Daniel C. Grove, MD et. al.

Jul 28th, 2022 - To the Editor: Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by the formation of antihemidesmosomal antibodies, resulting in tense bullae concentrated on the extremities and trunk that often are preceded by a pruritic u.

‘Time Is Blood’: Researchers Devise Shortcut to AHA Diagnosis
https://www.medscape.com/viewarticle/972442

Apr 20th, 2022 - Because they have detected sluggishness in hospital diagnoses, researchers have developed an algorithm to help clinicians determine whether patients have acquired hemophilia A (AHA), a rare bleeding disorder that mainly affects elderly men with me...

‘Time is blood’: Researchers devise shortcut to AHA diagnosis
https://www.mdedge.com/hematology-oncology/article/253869/bleeding-disorders/time-blood-researchers-devise-shortcut-aha
Randy Dotinga

Apr 18th, 2022 - Because they have detected sluggishness in hospital diagnoses, researchers have developed an algorithm to help clinicians determine whether patients have acquired hemophilia A (AHA), a rare bleeding disorder that mainly affects elderly men with me.

Post–COVID Vaccine AHA Cases Raise Eyebrows in Italy
https://www.medscape.com/viewarticle/968826

Feb 18th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Four cases of acquired hemophilia A (AHA) identified after SARS-CoV-2 immunizations in a province in northern Italy caught the attention of resear...

Post–COVID vaccine AHA cases raise eyebrows in Italy
https://www.mdedge.com/hematology-oncology/article/251919/bleeding-disorders/post-covid-vaccine-aha-cases-raise-eyebrows
Sharon Worcester

Feb 17th, 2022 - Four cases of acquired hemophilia A (AHA) identified after SARS-CoV-2 immunizations in a province in northern Italy caught the attention of researchers, who stressed that the cases are “unusual,” but not necessarily caused by vaccination. “The ove.

see more →

Patient Education  2 results see all →